GB9805561D0 - A combination of therapeutic agents - Google Patents

A combination of therapeutic agents

Info

Publication number
GB9805561D0
GB9805561D0 GBGB9805561.9A GB9805561A GB9805561D0 GB 9805561 D0 GB9805561 D0 GB 9805561D0 GB 9805561 A GB9805561 A GB 9805561A GB 9805561 D0 GB9805561 D0 GB 9805561D0
Authority
GB
United Kingdom
Prior art keywords
combination
therapeutic agents
therapeutic
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9805561.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Original Assignee
Merck Sharp and Dohme Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd filed Critical Merck Sharp and Dohme Ltd
Priority to GBGB9805561.9A priority Critical patent/GB9805561D0/en
Publication of GB9805561D0 publication Critical patent/GB9805561D0/en
Priority to EP99909095A priority patent/EP1061952A2/en
Priority to JP2000536371A priority patent/JP2002506815A/en
Priority to CA002323618A priority patent/CA2323618A1/en
Priority to PCT/GB1999/000778 priority patent/WO1999047131A2/en
Priority to AU28464/99A priority patent/AU753077B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9805561.9A 1998-03-16 1998-03-16 A combination of therapeutic agents Ceased GB9805561D0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
GBGB9805561.9A GB9805561D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents
EP99909095A EP1061952A2 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
JP2000536371A JP2002506815A (en) 1998-03-16 1999-03-16 Combination of GABAAα5 inverse agonist and acetylcholinesterase inhibitor
CA002323618A CA2323618A1 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
PCT/GB1999/000778 WO1999047131A2 (en) 1998-03-16 1999-03-16 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
AU28464/99A AU753077B2 (en) 1998-03-16 1999-03-16 Combination of a GABA-A alpha 5 inverse agonist and an acetylcholinesterase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9805561.9A GB9805561D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents

Publications (1)

Publication Number Publication Date
GB9805561D0 true GB9805561D0 (en) 1998-05-13

Family

ID=10828631

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9805561.9A Ceased GB9805561D0 (en) 1998-03-16 1998-03-16 A combination of therapeutic agents

Country Status (6)

Country Link
EP (1) EP1061952A2 (en)
JP (1) JP2002506815A (en)
AU (1) AU753077B2 (en)
CA (1) CA2323618A1 (en)
GB (1) GB9805561D0 (en)
WO (1) WO1999047131A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6380210B1 (en) 1999-04-02 2002-04-30 Neurogen Corporation Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6271241B1 (en) 1999-04-02 2001-08-07 Neurogen Corporation Cycloalkyl and aryl fused aminoalkyl-imidazole derivatives: modulators and GLP-1 receptors
US6627624B1 (en) 1999-04-02 2003-09-30 Neurogen Corporation Aryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa receptors
US6281237B1 (en) 1999-04-02 2001-08-28 Neurogen Corporation N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives
AU2001264932A1 (en) 2000-05-26 2001-12-11 Neurogen Corporation Oxo-imidazopyrimidine-carboxamides and their use as gaba brain receptor ligands
US6828329B2 (en) 2000-06-26 2004-12-07 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
IL159811A0 (en) 2001-07-13 2004-06-20 Neurogen Corp Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands
EP1585520A1 (en) * 2002-12-24 2005-10-19 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
US20050267076A1 (en) * 2004-05-14 2005-12-01 Johns Hopkins University Method for improving cognitive function
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
ATE554085T1 (en) 2006-11-30 2012-05-15 Probiodrug Ag NEW INHIBITORS OF GLUTAMINYL CYCLASE
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US20110212928A1 (en) 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
ES2586231T3 (en) 2010-03-03 2016-10-13 Probiodrug Ag Glutaminyl cyclase inhibitors
CN102791704B (en) 2010-03-10 2015-11-25 前体生物药物股份公司 The heterocycle inhibitor of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6899043B2 (en) 2015-05-22 2021-07-07 エージンバイオ， インコーポレイテッド Sustained release pharmaceutical composition of levetiracetam
KR101743960B1 (en) * 2015-07-06 2017-06-08 서울대학교산학협력단 G 19 Pharmaceutical composition for preventing treating or retarding Alzheimers disease or dementia comprising G protein-Coupled Receptor19 agonist as an active ingredient
PL3461819T3 (en) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitors of glutaminyl cyclase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647580A (en) * 1985-07-18 1987-03-03 Syntex (U.S.A.) Inc. Treatment of Alzheimer's disease
GB9503601D0 (en) * 1995-02-23 1995-04-12 Merck Sharp & Dohme Method of treatment and method of manufacture of medicament
WO1998004560A1 (en) * 1996-07-25 1998-02-05 Merck Sharp & Dohme Limited SUBSTITUTED TRIAZOLO PYRIDAZINE DERIVATIVES AS INVERSE AGONISTS OF THE GABAAα5 RECEPTOR SUBTYPE

Also Published As

Publication number Publication date
WO1999047131A3 (en) 1999-11-04
AU753077B2 (en) 2002-10-10
JP2002506815A (en) 2002-03-05
CA2323618A1 (en) 1999-09-23
EP1061952A2 (en) 2000-12-27
WO1999047131A2 (en) 1999-09-23
AU2846499A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
GB9805561D0 (en) A combination of therapeutic agents
GB9820113D0 (en) Therapeutic agents
GB9708484D0 (en) Therapeutic agents
GB9708945D0 (en) Therapeutic agents
GB9816263D0 (en) Therapeutic agents
GB9806102D0 (en) Therapeutic agents
GB9704948D0 (en) Therapeutic agents
GB9702524D0 (en) Therapeutic agents
GB9711753D0 (en) Therapeutic agents
GB9713707D0 (en) Therapeutic agents
GB9808663D0 (en) Therapeutic agents
GB9711114D0 (en) Therapeutic agents
GB9801234D0 (en) Therapeutic agents
GB9813576D0 (en) Therapeutic agents
GB9813006D0 (en) Therapeutic agents
GB9801210D0 (en) Therapeutic agents
AP9901436A0 (en) Therapeutic agents
GB9801397D0 (en) Therapeutic agents
GB9702392D0 (en) Therapeutic agents
GB9805557D0 (en) A combination of therapeutic agents
GB9801202D0 (en) Therapeutic agents
GB9700555D0 (en) Therapeutic agents
GB9810092D0 (en) Therapeutic agents
GB9819484D0 (en) Therapeutic agents
GB9811879D0 (en) Therapeutic agents

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)